Zinzino recently announced revenue of SEK 794.4 million for the second quarter of 2025, compared to SEK 507.0 million in the same period last year. This represents a 57% increase in reported sales, with growth of 62% in local currencies.
EBITDA rose to SEK 79.7 million from SEK 63.0 million, while the EBITDA margin stood at 10.0% compared to 12.4% in Q2 2024.
During the quarter, Zinzino made important moves to expand its distribution power in Europe. The company acquired the assets of Valentus Global and Ecosystem SAS, strengthening its international reach.
In Asia, Zinzino achieved full market status in the Philippines and launched operations in China with a locally adapted concept, further supporting its long-term global growth strategy.
Revenue: SEK 794.4M (507.0M), growth of 57%
Gross Profit: SEK 247.9M (174.5M), margin 31.2%
EBITDA: SEK 79.7M (63.0M), margin 10.0%
Cash Flow from Operations: SEK 112.6M (93.2M)
Revenue: SEK 1,518.1M (961.6M), growth of 58%
Gross Profit: SEK 471.5M (335.4M), margin 31.1%
EBITDA: SEK 158.4M (114.7M), margin 10.4%
Cash Flow from Operations: SEK 133.7M (91.5M)
Cash & Cash Equivalents: SEK 408.5M (296.0M)
Zinzino is a global direct sales company headquartered in Gothenburg, Sweden, specializing in test-based, personalized nutrition and scientific skincare. Listed on the Nasdaq First North Premier Growth Market, Zinzino operates in more than 100 international markets.
The company has expanded through strategic acquisitions, including all assets of Zurvita and Xelliss, as well as co-ownership in the Cypriot olive oil producer Cleanthi Alpha-Olenic LTD. Zinzino also owns HANZZ+HEIDII (Swiss biotech skincare), BioActive Foods AS, and Faun Pharma AS in Norway.
Get more information
There are no reviews yet. Be the first one to write one.
